Related Experiment Video
Updated: Jan 22, 2026
Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
Published on: January 31, 2025
Fanconi anemia complementation group C gene (FANCC) association with hereditary and sporadic renal tumors
Devashish Desai1, Rebecca A Sager2, Michael Basin2
1Division of Hematology and Oncology, Department of Hematology and Medical Oncology, SUNY Upstate Medical University, Syracuse, NY, USA.
Background:
Inactivating genomic alterations (GA) of the FANCC gene are associated with genomic instability, DNA cross-linking, and homologous DNA repair deficiency. Here, we evaluated the incidence of FANCC GA in renal tumors (RT).
Methods:
A total of 463 546 clinically advanced cancer (CAC) cases underwent hybrid capture-based comprehensive genomic profiling using the FDA-approved F1CDx assay to detect all classes of GA. Microsatellite instability (MSI) status, tumor mutational burden (TMB), genomic loss of heterozygosity, prediction of germline status, and genomic signature were determined with algorithm-based analysis.
Results:
Clinically advanced cancers (0.43% of 1993) featured FANCC GA; 27 of these FANCC-mutated tumors (20 males, mean age 57) were RT (0.35% of 7668 RT). The primary tumor was sequenced in 9 cases and a metastatic site in 18 (5 lymph nodes, 4 soft tissues, 3 brains, 2 livers, 1 each lung, adrenal, eye, bone). Only 1 of 25 tested FANCC-mutated RT was MSI-high; 4 cases (15%) featured TMB ≥10 mutations/Mb. The genomic signature could be assessed in 5 cases: 4 were MMR-deficient. The FANCC mutations included inactivating short variant mutations in 24 cases (10 nonsense, 10 frameshift, 2 non-frame, and 2 splice-site mutations) and 3 truncating rearrangements (FANCC: SUSD3, FANCC: FANCC, and FANCC: C20orf24). Interestingly, 14 (52%) of the FANCC-mutated RT were predicted to be germline.
Conclusions:
Somatic and germline mutations in FANCC occur in an exceedingly small subset of clinically advanced RT but at a similar rate to other cancers, and the genomic landscape does not appear to be different from RT with wild-type FANCC. Germline testing is warranted, as we see a high frequency of germline FANCC mutations.
Patient Summary:
Our study highlights the rate of FANCC mutation in kidney cancer, which may be a therapeutic target and awaits further assessment and drug development. Also, it shows that FANCC mutations are more germline, requiring further genetic testing.
Related Concept Videos
01:27Complement System
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
00:49Complementation Tests
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:07Organization of Genes
01:21Association Areas of the Cortex
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...